Lupin Gains Nearly 1% As Subsidiary Gets New Drug Approval

Lupin shares edged higher by around half a per cent after its subsidiary received supplemental new drug application approval from the US regulator. The United States Food and Drug Administration (USFDA) approved Lupin's US-based arm's supplemental new drug application (sNDA) to expand the use of Solosec for treating trichomoniasis in adults, Lupin said in a regulatory filing to the stock exchanges.